Wang Y Z, Ning Z Q, Zhang Q X
Department of Oncology, Beijing Institute of Radiation Medicine, China.
Immunol Lett. 1993 Aug;37(2-3):229-33. doi: 10.1016/0165-2478(93)90035-z.
By means of cytotoxicity and thymidine uptake assays, the effect of human recombinant interleukin-2 (rIL-2) on the induction of lymphokine-activated killer (LAK) cell activity and cellular proliferation in splenocytes and thymocytes from human fetuses (18-22 weeks) was studied and compared with that in mononuclear cells from adult peripheral blood. It was shown that the fetal splenocytes and thymocytes incubated with low doses of rIL-2 (10-100 U/ml) developed a broad spectrum of antitumor activity (LAK cytotoxicity), although the kinetics and magnitudes of the responses were different. It was also suggested that LAK precursors were present in fetal spleen and thymus. Furthermore, rIL-2 induced a stronger proliferative and cytotoxic response in splenocytes than in thymocytes. The human fetal LAK cells isolated from the spleen were found to be 10-20 times more potent than those from adult peripheral blood with regard to cell proliferation and cytotoxicity in vitro.
通过细胞毒性和胸腺嘧啶核苷摄取试验,研究了人重组白细胞介素-2(rIL-2)对人胎儿(18 - 22周)脾细胞和胸腺细胞中淋巴因子激活的杀伤(LAK)细胞活性诱导及细胞增殖的影响,并与成人外周血单个核细胞进行了比较。结果表明,低剂量rIL-2(10 - 100 U/ml)孵育的胎儿脾细胞和胸腺细胞产生了广泛的抗肿瘤活性(LAK细胞毒性),尽管反应的动力学和程度有所不同。还提示胎儿脾脏和胸腺中存在LAK前体细胞。此外,rIL-2诱导脾细胞产生的增殖和细胞毒性反应比胸腺细胞更强。从脾脏分离的人胎儿LAK细胞在体外细胞增殖和细胞毒性方面比成人外周血来源的LAK细胞强10 - 20倍。